Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45

Rhea-AI Filing Summary

Niagen Bioscience, Inc. director Patrick Kristin received a grant of stock options representing the right to buy 31,746 shares of common stock. The options have an exercise price of $3.4500 per share and vest 100% on June 24, 2027. After this grant, he holds 31,746 derivative securities linked to common stock, and the options expire on June 23, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patrick Kristin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	31,746	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 31,746 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,746 options Exercise price: $3.4500 per share Underlying common shares: 31,746 shares +3 more

6 metrics

Option grant size 31,746 options Stock Option (right to buy) granted to director

Exercise price $3.4500 per share Conversion or exercise price of the options

Underlying common shares 31,746 shares Common Stock underlying the stock options

Post‑grant derivative holdings 31,746 derivative securities Total shares following transaction

Vesting date June 24, 2027 Option vests 100% on this date

Expiration date June 23, 2036 Option expiration for the stock option grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vests 100%

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "3.4500" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests 100% financial

"Footnote: "Option vests 100% on June 24, 2027.""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 05:57 PM Accepted by SEC EDGAR 06/26/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patrick Kristin

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.45	06/24/2026		A		31,746		06/24/2027(1)	06/23/2036	Common Stock	31,746	$0	31,746	D

Explanation of Responses:

1. Option vests 100% on June 24, 2027.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Niagen Bioscience (NAGE) report for Patrick Kristin?

Niagen Bioscience reported that director Patrick Kristin received a grant of stock options for 31,746 underlying common shares. These options were awarded at a fixed exercise price and represent compensation rather than an open‑market stock purchase or sale.

How many Niagen Bioscience stock options were granted to Patrick Kristin?

Patrick Kristin was granted stock options covering 31,746 shares of Niagen Bioscience common stock. This entire amount is new derivative equity compensation and matches his total derivative holdings reported following the transaction on the Form 4 filing.

What is the exercise price of Patrick Kristin’s Niagen Bioscience options?

The granted stock options have an exercise price of $3.4500 per share. This is the price at which Kristin may buy Niagen Bioscience common stock if he exercises the options after they vest, subject to the option terms and expiration date.

When do Patrick Kristin’s Niagen Bioscience options vest and expire?

The option award to Patrick Kristin vests 100% on June 24, 2027. The options expire on June 23, 2036, giving him a limited window after vesting to exercise his right to purchase common shares at the stated price.

Did Patrick Kristin buy or sell Niagen Bioscience shares in this Form 4?

This Form 4 reflects a grant of stock options, not an open‑market buy or sell of common shares. The transaction is coded as a grant or award acquisition, meaning it represents equity compensation rather than a discretionary market trade.